Zolpidem Tablet-in-Tablet Formulation for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing zolpidem tablet formulations, such as bilayer and compression-coated tablets, face issues with separation during handling, economic inefficiencies, and challenges in achieving robustness and stability for large-scale production, particularly in maintaining adequate hardness and low friability.
Innovation Solution
A zolpidem tablet-in-tablet dosage form with a controlled release inner core and an immediate release outer coating layer, where the mass of the coating layer is significantly greater than the core, and contains a substantial amount of binder to ensure stability and adhesion, allowing for direct compression without granulation, thus enhancing robustness and reducing handling issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a bilayer tablet formulation is used to provide controlled release, then the duration of action is extended, but the tablet layers may separate during handling and film coating is essentially necessary
Solution Approach 1:
The patent applies the nesting principle by placing the controlled release core tablet inside an outer immediate release coating layer, creating a tablet-in-tablet structure. The inner core contains zolpidem tartrate in a controlled release matrix, while the outer layer provides immediate release and protects the core during handling and storage, preventing separation issues associated with bilayer tablets.
Solution Approach 2:
The patent segments the dosage form into two distinct functional components: an inner controlled release core and an outer immediate release coating layer. This segmentation allows each layer to perform its specific function independently while maintaining structural integrity through the compression coating process.
2Duration of action of moving object
If wet granulation is used to form granulate for compression into tablet layers, then the controlled release formulation can be achieved, but the manufacturing process becomes less economical
Solution Approach 1:
The patent extracts the granulation step from the manufacturing process by using direct compression to form both the inner core tablet and the outer coating layer. This eliminates the need for wet granulation, reducing process complexity and manufacturing costs while maintaining the controlled release functionality through the tablet-in-tablet structure.
3Reliability
If the outer coat mass is increased relative to the core to improve adhesion, then the tablet structure becomes more stable, but the manufacturing complexity increases
Solution Approach 1:
The patent optimizes the mass ratio parameter between the outer coating layer and inner core, specifying that the coating layer mass should be at least 1.5 times the core mass. This parameter optimization ensures adequate adhesion and structural stability while maintaining manufacturing simplicity through direct compression, avoiding the need for complex multi-step processes.
Data Source
AI summary
A zolpidem tablet having modified release is designed as a tablet-in-tablet dosage form.